Literature DB >> 2159768

DNA index, S-phase fraction, histological grade and prognosis in breast cancer.

S M O'Reilly1, R S Camplejohn, D M Barnes, R R Millis, D Allen, R D Rubens, M A Richards.   

Abstract

DNA index and S-phase fraction (SPF) were measured by flow cytometry on paraffin embedded tissue from 140 primary breast tumours. The results of DNA analysis were compared with the size, degree of axillary node involvement, histological grade and steroid receptor content of the tumours, as well as with the patients' subsequent clinical course. Forty-four (31.4%) of the 140 tumours were diploid. S-phase fraction was evaluable for 134 (95.7%). The median SPF of the whole population was 7.1%, with diploid tumours having a significantly lower median SPF (3.2%) than aneuploid (10.1%, P less than 0.001). Both aneuploidy (P = 0.002) and high SPF (P less than 0.001) were strongly associated with high histological grade. There was no significant association between either DNA ploidy or SPF and tumour size, nodal status or steroid receptor content. An SPF below the median was strongly associated with better relapse-free survival (P = 0.008), overall survival (P = 0.004) and survival after relapse (P less than 0.001). Ploidy did not correlate significantly with clinical course. Multivariate analysis using the Cox model suggested that, while SPF gave prognostic information independent of tumour size or nodal status, this independent significance was lost when histological grade was included in the analysis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2159768      PMCID: PMC1971595          DOI: 10.1038/bjc.1990.152

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle.

Authors:  H Baisch; W Göhde; W A Linden
Journal:  Radiat Environ Biophys       Date:  1975-06-13       Impact factor: 1.925

2.  Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation.

Authors:  B Fisher; R G Ravdin; R K Ausman; N H Slack; G E Moore; R J Noer
Journal:  Ann Surg       Date:  1968-09       Impact factor: 12.969

3.  Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer.

Authors:  J F Stewart; R J King; S A Sexton; R R Millis; R D Rubens; J L Hayward
Journal:  Eur J Cancer       Date:  1981-04       Impact factor: 9.162

4.  Association between steroid hormone receptor status and disease-free interval in breast cancer.

Authors:  J C Allegra; M E Lippman; R Simon; E B Thompson; A Barlock; L Green; K K Huff; H M Do; S C Aitken; R Warren
Journal:  Cancer Treat Rep       Date:  1979-08

5.  A comparison of human breast cancer cell kinetics measured by flow cytometry and thymidine labeling.

Authors:  R W McDivitt; K R Stone; R B Craig; J S Meyer
Journal:  Lab Invest       Date:  1985-03       Impact factor: 5.662

6.  Relationship of flow cytometry results to clinical and steroid receptor status in human breast cancer.

Authors:  T E Kute; H B Muss; M Hopkins; R Marshall; D Case; L Kammire
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

7.  Progesterone and estrogen receptors as prognostic variables in breast cancer.

Authors:  B H Mason; I M Holdaway; P R Mullins; L H Yee; R G Kay
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

8.  Primary breast cancer. Flow cytometric DNA pattern in relation to clinical and histopathologic characteristics.

Authors:  E Thorud; S D Fosså; S Vaage; O Kaalhus; O S Knudsen; O Børmer; M C Shoaib
Journal:  Cancer       Date:  1986-02-15       Impact factor: 6.860

9.  Correlation of cell-cycle kinetics, hormone receptors, histopathology, and nodal status in human breast cancer.

Authors:  R E Moran; M M Black; L Alpert; M J Straus
Journal:  Cancer       Date:  1984-10-15       Impact factor: 6.860

10.  Intralaboratory variations in the grading of breast carcinoma.

Authors:  G S Delides; G Garas; G Georgouli; D Jiortziotis; J Lecca; T Liva; J Elemenoglou
Journal:  Arch Pathol Lab Med       Date:  1982-03       Impact factor: 5.534

View more
  19 in total

1.  Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ.

Authors:  D M Barnes; J S Meyer; J G Gonzalez; W J Gullick; R R Millis
Journal:  Breast Cancer Res Treat       Date:  1991-03       Impact factor: 4.872

2.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

3.  Relation between deletion of chromosome 1p36 and DNA ploidy in breast carcinoma: an interphase cytogenetic study.

Authors:  F Farabegoli; N Baldini; D Santini; C Ceccarelli; M Taffurelli; D Treré; M Derenzini
Journal:  Clin Mol Pathol       Date:  1996-04

4.  Tumour heterogeneity of DNA cell cycle variables in breast cancer measured by flow cytometry.

Authors:  E Bergers; P J van Diest; J P Baak
Journal:  J Clin Pathol       Date:  1996-11       Impact factor: 3.411

5.  Proliferating cell nuclear antigen in breast lesions: correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer.

Authors:  P Shrestha; K Yamada; T Wada; S Maeda; M Watatani; M Yasutomi; H Takagi; M Mori
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

6.  Markers of prognosis in breast cancer--the relationship between binding of the lectin HPA and histological grade, SPF, and ploidy.

Authors:  S A Brooks; A J Leathem; R S Camplejohn; W Gregory
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 7.  DNA Cytometry Consensus Conference. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast.

Authors:  D W Hedley; G M Clark; C J Cornelisse; D Killander; T Kute; D Merkel
Journal:  Breast Cancer Res Treat       Date:  1993-10       Impact factor: 4.872

8.  Genetic evolution of breast cancers. III: Age-dependent variations in the correlations between biological indicators of prognosis.

Authors:  Y Remvikos; H Magdelenat; B Dutrillaux
Journal:  Breast Cancer Res Treat       Date:  1995-04       Impact factor: 4.872

Review 9.  Taxane benefit in breast cancer--a role for grade and chromosomal stability.

Authors:  Roger P A'Hern; Mariam Jamal-Hanjani; A Marcell Szász; Stephen R D Johnston; Jorge S Reis-Filho; Rebecca Roylance; Charles Swanton
Journal:  Nat Rev Clin Oncol       Date:  2013-05-07       Impact factor: 66.675

10.  Proliferative behaviour of an oestrogen sensitive rat mammary tumour: evidence for a paracrine interaction between tumour and stroma.

Authors:  M G Ormerod; J C Titley; T A Smith; A L Tombs; S Eccles
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.